Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Presentation TCT 2015

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Gregg W. Stone

October 13, 2015

Presentation TCT 2015

TCT 75: Cangrelor Improves Ischemic Outcomes in Patients With Multivessel Disease and Single Vessel Disease Undergoing PCI Insights From the CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Freddy Abnousi

October 13, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

Presentation TCT 2014

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Presenter: John M. Lasala, Stuart J. Pocock, Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Presenter: Deepak Bhatt

September 16, 2014

Presentation TCT 2014

YES: CHAMPION PHOENIX was Convincing!

Presenter: Deepak L. Bhatt

September 14, 2014

Presentation TCT 2013

Pro Position: The Data - Phoenix and Meta-Analysis of the Champion Clinical Trial Program!

Presenter: Philippe Gabriel Steg

October 31, 2013

Presentation TCT 2013

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Presenter: Philippe Gabriel Steg

October 31, 2013

News Conference News TCT 2013

Intraprocedural ST Predicts Adverse Short-Term Events

October 29, 2013

Presentation TCT 2013

CHAMPION PHOENIX IPST: Implications of Intraprocedural Stent Thrombosis During PCI from a Prospective, Randomized Trial of a Potent Intravenous ADP Antagonist vs. a Standard Ora...

Presenter: Philippe Généreux

October 28, 2013

Presentation TCT 2012

Cangrelor: CHAMPION PHOENIX Update

Presenter: Harvey White

October 24, 2012

Advertisement

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

TCT 75: Cangrelor Improves Ischemic Outcomes in Patients With Multivessel Disease and Single Vessel Disease Undergoing PCI Insights From the CHAMPION PHOENIX Trial

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

YES: CHAMPION PHOENIX was Convincing!

Pro Position: The Data - Phoenix and Meta-Analysis of the Champion Clinical Trial Program!

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Intraprocedural ST Predicts Adverse Short-Term Events

CHAMPION PHOENIX IPST: Implications of Intraprocedural Stent Thrombosis During PCI from a Prospective, Randomized Trial of a Potent Intravenous ADP Antagonist vs. a Standard Ora...

Cangrelor: CHAMPION PHOENIX Update

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content